Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
Kai M, Hikita H, Kazuki M, Tahata Y, Shinkai K, Doi A, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Kaneko A, Iio S, Nawa T, Kakita N, Morishita N, Hiramatsu N, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Oze T, Kodama T, Tatsumi T, Takehara T. Kai M, et al. Among authors: oze t. PLoS One. 2024 Jan 2;19(1):e0294590. doi: 10.1371/journal.pone.0294590. eCollection 2024. PLoS One. 2024. PMID: 38165900 Free PMC article.
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Nagase T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Imai Y, Kato M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Oze T, et al. J Gastroenterol. 2011 Jul;46(7):944-52. doi: 10.1007/s00535-011-0403-0. Epub 2011 May 7. J Gastroenterol. 2011. PMID: 21552988 Clinical Trial.
Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Kurokawa M, et al. Among authors: oze t. J Gastroenterol. 2012 May;47(5):577-85. doi: 10.1007/s00535-011-0522-7. Epub 2012 Jan 11. J Gastroenterol. 2012. PMID: 22231575 Clinical Trial.
Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma.
Kohga K, Tatsumi T, Tsunematsu H, Aono S, Shimizu S, Kodama T, Hikita H, Yamamoto M, Oze T, Aketa H, Hosui A, Miyagi T, Ishida H, Hiramatsu N, Kanto T, Hayashi N, Takehara T. Kohga K, et al. Among authors: oze t. Cancer Immunol Immunother. 2012 Sep;61(9):1425-32. doi: 10.1007/s00262-012-1208-6. Cancer Immunol Immunother. 2012. PMID: 22302133 Free PMC article.
Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.
Harada N, Hiramatsu N, Oze T, Yamada R, Kurokawa M, Miyazaki M, Yakushijin T, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, Takehara T. Harada N, et al. Among authors: oze t. J Gastroenterol. 2013 Apr;48(4):535-43. doi: 10.1007/s00535-012-0657-1. Epub 2012 Sep 14. J Gastroenterol. 2013. PMID: 22976932
Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T; Osaka Liver Forum. Oze T, et al. Clin Gastroenterol Hepatol. 2014 Jul;12(7):1186-95. doi: 10.1016/j.cgh.2013.11.033. Epub 2013 Dec 7. Clin Gastroenterol Hepatol. 2014. PMID: 24321207
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, Hikita H, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, Takehara T. Harada N, et al. Among authors: oze t. J Viral Hepat. 2014 May;21(5):357-65. doi: 10.1111/jvh.12151. Epub 2013 Aug 25. J Viral Hepat. 2014. PMID: 24716638
The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
Oze T, Hiramatsu N, Yakushijin T, Yamada R, Harada N, Morishita N, Yamada A, Oshita M, Kaneko A, Suzuki K, Inui Y, Tamura S, Yoshihara H, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hayashi N, Takehara T. Oze T, et al. J Gastroenterol. 2015 Mar;50(3):313-22. doi: 10.1007/s00535-014-0965-8. Epub 2014 May 8. J Gastroenterol. 2015. PMID: 24806033 Clinical Trial.
48 results